Cargando…

Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine

Detalles Bibliográficos
Autores principales: Rosen, Noah, Pearlman, Eric, Ruff, Dustin, Day, Kathleen, Nagy, Abraham Jim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594135/
https://www.ncbi.nlm.nih.gov/pubmed/30973202
http://dx.doi.org/10.1111/head.13514
_version_ 1783430196580319232
author Rosen, Noah
Pearlman, Eric
Ruff, Dustin
Day, Kathleen
Nagy, Abraham Jim
author_facet Rosen, Noah
Pearlman, Eric
Ruff, Dustin
Day, Kathleen
Nagy, Abraham Jim
author_sort Rosen, Noah
collection PubMed
description
format Online
Article
Text
id pubmed-6594135
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65941352019-07-10 Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine Rosen, Noah Pearlman, Eric Ruff, Dustin Day, Kathleen Nagy, Abraham Jim Headache Comments, Observations, and Rebuttals John Wiley and Sons Inc. 2019-04-11 2019-04 /pmc/articles/PMC6594135/ /pubmed/30973202 http://dx.doi.org/10.1111/head.13514 Text en © 2019 Eli Lilly & Co. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Comments, Observations, and Rebuttals
Rosen, Noah
Pearlman, Eric
Ruff, Dustin
Day, Kathleen
Nagy, Abraham Jim
Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
title Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
title_full Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
title_fullStr Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
title_full_unstemmed Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
title_short Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
title_sort response to misused and misleading: 100% response rate to galcanezumab in patients with episodic migraine
topic Comments, Observations, and Rebuttals
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594135/
https://www.ncbi.nlm.nih.gov/pubmed/30973202
http://dx.doi.org/10.1111/head.13514
work_keys_str_mv AT rosennoah responsetomisusedandmisleading100responseratetogalcanezumabinpatientswithepisodicmigraine
AT pearlmaneric responsetomisusedandmisleading100responseratetogalcanezumabinpatientswithepisodicmigraine
AT ruffdustin responsetomisusedandmisleading100responseratetogalcanezumabinpatientswithepisodicmigraine
AT daykathleen responsetomisusedandmisleading100responseratetogalcanezumabinpatientswithepisodicmigraine
AT nagyabrahamjim responsetomisusedandmisleading100responseratetogalcanezumabinpatientswithepisodicmigraine